胰腺癌诊断前处方模式:回顾性初级保健队列研究
本研究基于英格兰2011-2018年确诊胰腺癌患者的初级保健与癌症登记链接数据,分析诊断前5年处方记录。止吐药、抗反流药和镇痛药处方也在诊断前数月增加,提示可借此提前发现胰腺癌。
要点
- 胰岛素处方在胰腺癌诊断前19个月开始增加,女性25个月、男性11个月。
- 抗反流药和 opioid 镇痛药处方在诊断前7个月增加,止吐药和非 opioid 镇痛药在5个月增加。
- 初级保健中因止吐、抗反流或镇痛药处方就诊的患者,可能提供早期诊断机会。
核心结论
- 胰岛素处方早期增加提示肿瘤诱导的3c型糖尿病,为小部分患者提供早期诊断机会。
- 初级保健中因止吐药、抗反流药和镇痛药处方就诊的患者也存在早期诊断和转诊机会。
研究设计与样本
- 回顾性队列研究,使用英格兰2011-2018年确诊胰腺癌患者的初级保健与癌症登记链接数据。
- 采用泊松回归估计处方增加高于基线的拐点。
主要发现
- 胰岛素处方在诊断前19个月增加(95%CI=14.2-23.8),女性25个月(95%CI=17.4-32.5)早于男性11个月(95%CI=5.8-16.2)。
- 其他降糖药处方在诊断前13个月增加(95%CI=7.7-18.5)。
- 抗反流药和 opioid 镇痛药处方在诊断前7个月增加(95%CI分别为5.4-8.6和4.4-9.6)。
- 止吐药和非 opioid 镇痛药处方在诊断前5个月增加(95%CI分别为2.9-7.1和3.2-6.8)。
临床怎么用
- 对初级保健中因止吐药、抗反流药或镇痛药新发/增加处方就诊的患者,应警惕胰腺癌可能。
- 对胰岛素新开始或剂量增加的患者,尤其女性,需考虑肿瘤诱导的3c型糖尿病并评估胰腺癌风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prescribing patterns in primary care could demonstrate early clinical features of cancer and windows of opportunity for timely investigation. AIM: To analyse primary care prescription patterns before a pancreatic cancer diagnosis. DESIGN AND SETTING: Retrospective cohort study using linked primary care and cancer registry data from patients diagnosed with pancreatic cancer in England between 2011 and 2018. METHOD: Prescription records registered in the Clinical Practice Research Datalink were analysed in the 5 years prediagnosis. Eight categories of prescriptions that may be used to treat clinical features of pancreatic cancer were included (anti-emetics, anti-reflux medications, insulin, other hypoglycaemic agents, opioids, non-opioid analgesics, neuropathic analgesics, and non-steroidal anti-inflammatories). Poisson regression was used to estimate the inflection points for increased prescribing above baseline. RESULTS: Among 12 990 patients, 669 287 prescriptions were analysed. Insulin was the least common prescription (6.9% [n = 892/12 990] of patients), anti-reflux the most common (52.6% [n = 6833/12 990] of patients). Insulin prescribing increased 19 months prediagnosis (95% confidence interval [CI] = 14.2 to 23.8), rising earlier in female patients (25 months; 95% CI = 17.4 to 32.5) than male patients (11 months; 95% CI = 5.8 to 16.2). Prescriptions for other hypoglycaemic agents increased 13 months (95% CI = 7.7 to 18.5), anti-reflux and opioid analgesic prescribing 7 months (95% CI = 5.4 to 8.6 and 4.4 to 9.6, respectively), and anti-emetics and non-opioid analgesics 5 months (95% CI = 2.9 to 7.1 and 3.2 to 6.8, respectively) before diagnosis. CONCLUSION: The early increase in insulin prescribing suggests tumour-induced type 3c diabetes, highlighting an opportunity for earlier diagnosis in a small proportion of patients. Opportunities for earlier diagnosis through investigation and referral also exist in patients prescribed anti-emetic, anti-reflux, and analgesic medications in primary care.
引用
- Morel C, Walter FM, Virpal P, et al. Prediagnostic prescription patterns in pancreatic cancer: a retrospective primary care cohort study. Br J Gen Pract. 2026. PMID: 41991223. doi:10.3399/BJGP.2025.0780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。